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Enabling omic technologies adopt a holistic view to produce unprecedented insights into the
molecular underpinnings of health and disease, in part, by generating massive highdimensional biological data. Leveraging these systems-level insights as an engine driving the
healthcare evolution is maximized through integration with medical, demographic, and
environmental datasets from individuals to populations. Big data analytics has accordingly
emerged to add value to the technical aspects of storage, transfer, and analysis required for
merging vast arrays of omic-, clinical- and eco-datasets. In turn, this new field at the interface
of biology, medicine, and information science is systematically transforming modern
therapeutics across discovery, development, regulation, and utilization.
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“…a man’s discourse was like to a rich Persian carpet, the beautiful figures and
patterns of which can be shown only by spreading and extending it out; when it is contracted
and folded up, they are obscured and lost”
Themistocles quoted by Plutarch AD 46 – AD 120
Like the tapestry in Plutarch’s quote, we can only comprehend the intricate patterns
that constitute wellness and disease by spreading out and extending the multi-dimensional
components that form the fabric of these processes. Implied in this self-evident concept is the
ability to collect the relevant data, deconvolute that data into comprehensible elements,
reassemble these elements into distinguishable patterns, and provide this new knowledge in a
form that is readily accessible to end-users, including patients, practitioners and regulators.1
The emergence of enabling medical technologies has revolutionized our ability to precisely
define the detailed characteristics of individuals in sickness and health. Omic technologies offer
a view of organization and function at the level of integrated molecular systems while next
generation imaging imparts structure to those systems at cell, tissue, organ and organismal
levels.2 Beyond these biological determinants, environmental elements that provide the
context for molecular structure and function and, ultimately, shape pathobiology are
memorialized in the longitudinal electronic health record (EHR).3 Together, these biological and
environmental data elements encode the information that predicts wellness, identifies disease
risk, personalizes healthcare interventions, and prevents untoward adverse therapeutic events.
While these individual data elements form the matrix that defines the mechanisms
underlying health and disease, a complete picture of these processes emerges only from their
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integration. Like a painting created in the style of the 19th century Pointillism technique, the
entire picture only comes into view when one steps away from the canvas and coalesces the
individual dots into a coherent image. In the context of biological and clinical data, the full
picture of (patho)physiology emerges when these elements are integrated across individual
patients and populations. The attendant challenges associated with this necessary data
integration can be appreciated by considering the sheer magnitude of the task. In 2012, the
worldwide digital healthcare data burden was estimated to be ~500 petabytes and is expected
to reach 25,000 petabytes (~1019 kB) in 2020.4 For comparison, the human brain stores ~2
petabytes of data while the largest single data storage facility is ~100 petabytes. In that context,
it has become easier and cheaper to generate data than to store, integrate and analyze it.5
This avalanche of high dimensional data at the interface of biology, medicine, and
healthcare delivery holds the potential to transform the therapeutics continuum of discovery,
development, regulation, and utilization (DDRU).6 As highlighted in the Commentary by
Schneweiss, this informational nexus is poised to provide unprecedented insights into the
pathobiology of disease, transform drug discovery and development, and revolutionize the
ability of regulatory agencies to maintain the highest standards of drug safety, all focused on
providing the best care precisely tailored to each individual patient.7 However, these large and
complex data sets are difficult to process using common database management tools or
traditional data processing applications, especially with respect to data capture, storage,
searching, sharing, integration and analysis. While the goal is to extract insights from complex,
noisy, and heterogeneous data sets, barriers have included the speed of data handling, curation
and the veracity of the data, the sheer volume of data, and the heterogeneity of data to be
4

integrated.7, 8 To address these challenges, big data analytics has emerged as a new discipline
innovating the tools, processes and procedures that create, manipulate, manage and integrate
very large heterogeneous data sets, to generate value from the whole that could not be
appreciated form the sum of the individual parts.7
The potential for big data to transform paradigms of disease pathobiology is exemplified
by the electronic health record (EHR), which in aggregate across the population represents an
extremely large collection of information generated in routine clinical care.4-6, 9 These datasets
are challenging to use because they are heterogeneous, representing digital data as well as
unstructured information, for example clinical notes. To optimize their utility, a new generation
of technologies and architectures has emerged to extract value from large volumes of complex
heterogeneous datasets through high-velocity capture, discovery and analysis.5 Analytic tools to
cull this information from these large collections of unstructured data include artificial
intelligence, natural-language processing, pattern recognition and machine learning.5 In that
context, in their review, Roden and Denny describe how coupling EHRs to genomic datasets
specifically enable discovery of genotype-phenotype associations which, in turn, can then be
implemented through EHRs to individualize patient care.9 They highlight the global character of
this effort, which includes their Electronic Medical Records and Genomics (eMERGE) Network,
as well as the Veterans Administration’s Million Veterans Program, the Kaiser-Permanente
GERA program, the UK Biobank, and the Icelandic deCODE resource.9, 10 Beyond their value in
discovering common genetic loci associated with human disease through genome-wide
association studies (GWAS), these resources also can be exploited to identify rare genetic
variants with large effect sizes, pleiotropic effects of common and rare genetic variants, and
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potential drug targets.11 One obstacle to the utility of EHRs for discovery research has been the
ability of these databases to accurately identify clinical phenotypes that could be used to
assemble true case and control cohorts to support meaningful genotype-phenotype
correlations.12 Indeed, for common diseases, where datasets could include hundreds of
thousands of subjects, electronic algorithms have been developed to overcome this obstacle
and extract true cases and control subjects, including the eMERGE’s Phenotype Knowledgebase
(PheKB.org) and i2b2 (informatics for integrating biology and the bedside).9-11 Employing these
approaches, drug response and adverse drug reaction phenotypes can be readily identified.
Importantly, beyond these genotype-phenotype associations, which typically start with a
defined disease (phenotype) to explore genomic associations, the constellation of phenotypes
represented within the collective EHR – the EHR phenome – can be interrogated for genomic
associations in phenome-wide association studies (Phe-WAS).9
The foregoing discussion underscores the potential for big data analytics as a resource
for discovery of new molecular associations, disease pathways, and pathophysiological
mechanisms. This is especially true in the context of integrating medical databases like the EHR
and clinically-annotated omic databases that associate disease phenotypes with molecular
features like genomics, epigenomics, transcriptomics, proteomics and metabolomics. As
highlighted in the review by Chen and Butte, such databases have been constructed and are
publically available to support an emerging in silico approach to drug discovery and
development.13 For example, transcriptomic analysis using data mining revealed that
expression of the protein MTBP was significantly elevated in breast cancer samples compared
to normal breast tissues and associated with poor survival.13 Indeed, this gene product could be
6

used to stratify breast cancer patients into clinically relevant subgroups and might represent a
new therapeutic target in these populations.13 Similarly, analysis of databases containing
genomic characteristics of thousands of tumors revealed >400 new defects that serve as driver
mutations that were previously unrecognized.13 Further, mapping these driver genes to drug
databases, including ChEMBL and ClinicalTrials.gov, revealed that >70% of patients could
benefit from novel agents in clinical development.13 Beyond discovery, these in silico
approaches also can be used to assess target druggability, through an integrative analysis of
protein function, homology to targets of approved drugs, three-dimensional structure, and the
existence of published active small molecules.13 Moreover, these analytic approaches can be
employed to compare similarities across different diseases, and the different drugs used to
treat them, to develop new indications for existing agents through the emerging approach of
computation drug repositioning.13 Together, these considerations highlight the potential of big
data analytic approaches to transform the science of drug discovery and development. 6, 13
Beyond discovery and development, big data analytics is revolutionizing the safety of
therapeutics at the level of regulation and utilization. As outlined in the Commentary by
Harpaz, DuMochel and Shah, pharmacovigilance currently depends on spontaneous adverse
event reporting from drug manufactures, health care professionals, and patients. 14 While this
type of reporting is essential to post-marketing surveillance, and effective at detecting ADRs, it
is a passive system fraught with delays in detecting and reporting, and a substantial number of
ADRs remain unreported.14 Big data analytics offers an unprecedented solution to improving
pharmacovigilance, providing unique mechanisms for adverse event detection and evaluation.
Some of the data sources to support this emerging field have been described earlier, for
7

example the very large collections of information in the EHR.7, 9 In that context, the EHR is the
backbone for the FDA’s Sentinel Initiative, described in the Commentary by Ball, Rob,
Anderson, and Dal Pan, which is creating a national network of databases to prospectively
monitor the safety of drugs and rapidly respond to emerging risks.14-16 This Sentinel System
currently comprises 18 partners, contains data on >170 million patients, and is earmarked to
expand.14, 16 Surprisingly, another evolving source of vast amounts of relevant information is
social media.5, 14 This real-time source of information includes health forums, social networks,
and online patient communities, with posts typically occurring proximal to the time an event
occurs.5,

14, 15, 17, 18

One example is the algorithm used by Google to track diseases, Google

Trends, which uses geospatial mapping to sift through enormous amounts of real-time data
vast quantities of information to identify clinically-relevant population-level events.5 For
example, Google Trends can identify peaks in search requests for terms like ‘flu symptoms’ and
‘flu treatments’ to identify an imminent disease outbreak in a geographic region even before
patients begin to task the regional health system.5 This example highlights the opportunities
offered by social media for adverse event surveillance that is global and real-time, to achieve
the earliest detection.
While big data analytics will transform every facet of the DDRU continuum, it is not
without significant challenges. There are the technical challenges of storage and transfer
speeds of an ever-growing body of heterogeneous information; developing algorithms that can
parse heterogeneous data with veracity so that downstream analyses are revealing; and
designing analytical tools that can integrate molecular, clinical, demographic, and
environmental elements that coalesce individual data points when the viewer steps away from
8

the canvas. However, an over-arching challenge in this emerging field remains the development
of tools to ensure the security of personal health information and scientific (e.g., genomic) data
to maintain the privacy of patients. This challenge can be appreciated by considering the
analogous problem of electronic fraud through identity theft, which is rampant in the
developed, electronically-dependent world. These challenges notwithstanding, the ability to
bring the power of vast amounts of electronic information to bear on the underpinnings of
health and disease, the development of new pharmacological interventions, and the safety of
the global formulary places biology and medicine on the verge of an exciting revolution.
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